• Diogo Matos Interno do Internato Complementar de Dermatologia e Venereologia/Resident, Dermatology and Venereology, Hospital Garcia de Orta, Almada, Portugal
  • João Alves Interno do Internato Complementar de Dermatologia e Venereologia/Resident, Dermatology and Venereology, Hospital Garcia de Orta, Almada, Portugal
  • Ana Marta António Interna do Internato Complementar de Dermatologia e Venereologia/Resident, Dermatology and Venereology, Hospital Garcia de Orta, Almada, Portugal
  • Elvira Bártolo Chefe de Serviço de Dermatologia e Venereologia, Directora do Serviço de Dermatologia e Venereologia/ Chief and Head of Dermatology and Venereology Department, Hospital Garcia de Orta, Almada, Portugal
Keywords: Melanoma, epidemiology, prevention and control


Introduction: The incidence of malignant melanoma has been rising. Therefore, the knowledge of its prevalence is very important. The authors intended to study the prevalence, demographic variables and the clinical features of the malignant melanoma diagnosed in their department.

Material and methods: A retrospective study of the MM diagnosed between 2006 and 2013 was performed. The data was statistically an analysed.

Results: three hundred and forty one malignant melanomas were diagnosed in 302 patients, 189 in women. The average annual growth rate was 8.57%, with 27 MM in 2006 and 48 in 2013. The older age groups predominated. Overall the trunk was the most frequent location. The Breslow thickness averaged 1.18mm. A statistically significant increase in the proportion of thin malignant melanomas (<1mm) was found. Nevertheless, the malignant melanomas >2mm remained unaltered. Nodal disease (stage III) was evident in 36 patients. Only two patients had metastatic disease (stage IV).

Discussion: The number of malignant melanomas diagnosed grew above the reported national and international incidence growth. The average Breslow thickness, above 1 mm, remains high. Nonetheless, the proportional increase in malignant melanomas <1mm points towards a positive evolution.

Conclusion: Our data, though representing a limited population, may lead to conclusions on the efficacy of the prevention strategies regarding malignant melanoma.


Download data is not yet available.


Registo Oncológico Nacional (RON-2001). Lisboa: Instituto Português de Oncologia Francisco Gentil; 2008.

RORENO. Registo Oncológico Nacional 2007. Porto: Instituto Português de Oncologia do Porto Francisco Gentil-EPE; 2013.

Amaro JA. Melanoma Maligno da Pele – Epidemiologia. In: Passos MJ, editor. Melanoma 2013. Lisboa; 2014. p.27-30.

Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al .SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. Disponível em:, based on November 2007 SEER data submission, posted to the SEER web site, 2008.

Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009; 27(1):3-9.

Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666-74.

Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol. 2010; 28(3):281-5.

Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012; 30(3):355-61.

Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62(2):118-28.

Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ. 2012. 24;345:e4757.

Waldmann A, Nolte S, Weinstock MA, Breitbart EW, Eisemann N, Geller AC, Greinert R, Volkmer B, Katalinic A. Skin cancer screening participation and impact on melanoma incidence in Germany-an observational study on incidence trends in regions with and without population-based screening. Br J Cancer. 2012; 106(5):970-4.

Tronnier M, Semkova K, Wollina U, Tchernev G. Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr. 2013; 163(15-16):354-8.

Kornek T, Augustin M. Skin cancer prevention. J Dtsch Dermatol Ges. 2013 ;11(4):283-96

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al . SEER Cancer Statistics Review, 1975-2011. National Cancer Institute. Disponível em:, based on November 2013 SEER

data submission, posted to the SEER web site, April 2014.

Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172(5):902-8.

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19(16):3622-34.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-206.

Furtado C, Macedo Ferreira A, Martinez C, Cochito M, Campos Lopes JM, Leite L. Cutaneous Melanoma. Review of 6 years. Skin Cancer. 1997; 12:177-82.

Catorze MG, Cabeças MA, Rafael M, Chaveiro A, Lamarão P, Cardoso J, Pacheco FA. Malignant melanoma(Epidemiological aspects of the casuistics in the department of Dermatology of a Lisbon Hospital: 1991-1997). Skin Cancer. 1998; 13:75-80.

Neto V, Rijo H, Cabrita J. Cutaneous malignant melanoma. Review of 11 years (1985-1995). Skin Cancer. 1999;14:145-55.

Alves R, Esteves T, Marote J, Caldeira C, Costa Neves P, Faria A. Malignant melanoma. Review of 7 years (1998-2004) at Hospital Central do Funchal. Skin Cancer. 2007; 22:181-9.

Ferreira M, Costa V, Torres T, Selores M. Análises retrospectiva de Melanoma Cutâneo primário: 1996-2006. Trab Soc Port Dermatol Venereol. 2007; 65(4):495-502.

Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol. 2007 ;56(5):768-73.

Armstrong A, Powell C, Powell R, Hallam N, Taylor J, Bird J, et al. Are we seeing the effects of public awareness campaigns? A 10-year analysis of Breslow thickness at presentation of malignant melanoma in the South West of England. J Plast Reconstr Aesthet Surg. 2014; 67(3):324-30.

Eisemann N, Waldmann A, Katalinic A. [Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan; 57(1):77-83.

Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol. 2001;14(5):280-90.

Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer. 2010; 126(2):450-8.

Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012; 118(21):5395-402.

Stratigos AJ, Forsea AM, van der Leest RJ, de Vries E, Nagore E, Bulliard JL, et al. Euromelanoma: a dermatology-led European campaign against non melanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol. 2012; 167 Suppl 2:99-104.

Aneja S, Brimhall AK, Kast DR, Aneja S, Carlson D, Cooper KD, et al. Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. Arch Dermatol. 2012; 148(11):1266-72.

Correia O, Duarte AF. Prevenção dos Cancros da Pele e do Melanoma. In: Passos MJ, editor. Melanoma 2013. Lisboa; 2014. p.39-47.

How to Cite
Matos, D., Alves, J., António, A. M., & Bártolo, E. (1). MALIGNANT MELANOMA: RETROSPECTIVE ANALYSIS 2006-2013. Journal of the Portuguese Society of Dermatology and Venereology, 73(1), 89-96.
Original Articles